184 related articles for article (PubMed ID: 35581445)
1. Cardioprotection by selective SGLT-2 inhibitors in a non-diabetic mouse model of myocardial ischemia/reperfusion injury: a class or a drug effect?
Nikolaou PE; Mylonas N; Makridakis M; Makrecka-Kuka M; Iliou A; Zerikiotis S; Efentakis P; Kampoukos S; Kostomitsopoulos N; Vilskersts R; Ikonomidis I; Lambadiari V; Zuurbier CJ; Latosinska A; Vlahou A; Dimitriadis G; Iliodromitis EK; Andreadou I
Basic Res Cardiol; 2022 May; 117(1):27. PubMed ID: 35581445
[TBL] [Abstract][Full Text] [Related]
2. Differential In Vitro Effects of SGLT2 Inhibitors on Mitochondrial Oxidative Phosphorylation, Glucose Uptake and Cell Metabolism.
Zügner E; Yang HC; Kotzbeck P; Boulgaropoulos B; Sourij H; Hagvall S; Elmore CS; Esterline R; Moosmang S; Oscarsson J; Pieber TR; Peng XR; Magnes C
Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35887308
[TBL] [Abstract][Full Text] [Related]
3. Chronic Empagliflozin Treatment Reduces Myocardial Infarct Size in Nondiabetic Mice Through STAT-3-Mediated Protection on Microvascular Endothelial Cells and Reduction of Oxidative Stress.
Nikolaou PE; Efentakis P; Abu Qourah F; Femminò S; Makridakis M; Kanaki Z; Varela A; Tsoumani M; Davos CH; Dimitriou CA; Tasouli A; Dimitriadis G; Kostomitsopoulos N; Zuurbier CJ; Vlahou A; Klinakis A; Brizzi MF; Iliodromitis EK; Andreadou I
Antioxid Redox Signal; 2021 Mar; 34(7):551-571. PubMed ID: 32295413
[No Abstract] [Full Text] [Related]
4. The SGLT-2 inhibitor empagliflozin improves myocardial strain, reduces cardiac fibrosis and pro-inflammatory cytokines in non-diabetic mice treated with doxorubicin.
Quagliariello V; De Laurentiis M; Rea D; Barbieri A; Monti MG; Carbone A; Paccone A; Altucci L; Conte M; Canale ML; Botti G; Maurea N
Cardiovasc Diabetol; 2021 Jul; 20(1):150. PubMed ID: 34301253
[TBL] [Abstract][Full Text] [Related]
5. Cardioprotective effects of empagliflozin after ischemia and reperfusion in rats.
Seefeldt JM; Lassen TR; Hjortbak MV; Jespersen NR; Kvist F; Hansen J; Bøtker HE
Sci Rep; 2021 May; 11(1):9544. PubMed ID: 33953281
[TBL] [Abstract][Full Text] [Related]
6. SGLT-2 Inhibition with Dapagliflozin Reduces the Activation of the Nlrp3/ASC Inflammasome and Attenuates the Development of Diabetic Cardiomyopathy in Mice with Type 2 Diabetes. Further Augmentation of the Effects with Saxagliptin, a DPP4 Inhibitor.
Ye Y; Bajaj M; Yang HC; Perez-Polo JR; Birnbaum Y
Cardiovasc Drugs Ther; 2017 Apr; 31(2):119-132. PubMed ID: 28447181
[TBL] [Abstract][Full Text] [Related]
7. Cardiovascular Effects of New Oral Glucose-Lowering Agents: DPP-4 and SGLT-2 Inhibitors.
Scheen AJ
Circ Res; 2018 May; 122(10):1439-1459. PubMed ID: 29748368
[TBL] [Abstract][Full Text] [Related]
8. Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts: inhibition of Na
Uthman L; Baartscheer A; Bleijlevens B; Schumacher CA; Fiolet JWT; Koeman A; Jancev M; Hollmann MW; Weber NC; Coronel R; Zuurbier CJ
Diabetologia; 2018 Mar; 61(3):722-726. PubMed ID: 29197997
[TBL] [Abstract][Full Text] [Related]
9. Rationale for the Early Use of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with Type 2 Diabetes.
Handelsman Y
Adv Ther; 2019 Oct; 36(10):2567-2586. PubMed ID: 31444707
[TBL] [Abstract][Full Text] [Related]
10. Sodium-glucose cotransporter 2 inhibitors antagonize lipotoxicity in human myeloid angiogenic cells and ADP-dependent activation in human platelets: potential relevance to prevention of cardiovascular events.
Spigoni V; Fantuzzi F; Carubbi C; Pozzi G; Masselli E; Gobbi G; Solini A; Bonadonna RC; Dei Cas A
Cardiovasc Diabetol; 2020 Apr; 19(1):46. PubMed ID: 32264868
[TBL] [Abstract][Full Text] [Related]
11. SGLT2 inhibitor dapagliflozin reduces endothelial dysfunction and microvascular damage during cardiac ischemia/reperfusion injury through normalizing the XO-SERCA2-CaMKII-coffilin pathways.
Ma L; Zou R; Shi W; Zhou N; Chen S; Zhou H; Chen X; Wu Y
Theranostics; 2022; 12(11):5034-5050. PubMed ID: 35836807
[No Abstract] [Full Text] [Related]
12. Acute dapagliflozin administration exerts cardioprotective effects in rats with cardiac ischemia/reperfusion injury.
Lahnwong C; Palee S; Apaijai N; Sriwichaiin S; Kerdphoo S; Jaiwongkam T; Chattipakorn SC; Chattipakorn N
Cardiovasc Diabetol; 2020 Jun; 19(1):91. PubMed ID: 32539724
[TBL] [Abstract][Full Text] [Related]
13. Empagliflozin and Dapagliflozin Increase Na
Dago M; Crespo-García T; Cámara-Checa A; Rapún J; Rubio-Alarcón M; Marín M; Tamargo J; Caballero R; Delpón E
Cells; 2022 Nov; 11(23):. PubMed ID: 36496967
[TBL] [Abstract][Full Text] [Related]
14. Simultaneous LC-MS/MS quantification of SGLT2 inhibitors and antipyrine in medium and tissue from human ex vivo placenta perfusions.
Kuoni S; Müller D; Simões-Wüst AP; Steiner R
J Chromatogr B Analyt Technol Biomed Life Sci; 2023 Aug; 1228():123841. PubMed ID: 37542935
[TBL] [Abstract][Full Text] [Related]
15. Sodium-glucose co-transporter-2 inhibitors and major adverse limb events: A trial-level meta-analysis including 51 713 individuals.
Huang CY; Lee JK
Diabetes Obes Metab; 2020 Dec; 22(12):2348-2355. PubMed ID: 32744411
[TBL] [Abstract][Full Text] [Related]
16. Sodium Glucose Co-Transporter 2 Inhibitors Ameliorate Endothelium Barrier Dysfunction Induced by Cyclic Stretch through Inhibition of Reactive Oxygen Species.
Li X; Römer G; Kerindongo RP; Hermanides J; Albrecht M; Hollmann MW; Zuurbier CJ; Preckel B; Weber NC
Int J Mol Sci; 2021 Jun; 22(11):. PubMed ID: 34205045
[TBL] [Abstract][Full Text] [Related]
17. Head-to-head comparison of two SGLT-2 inhibitors on AKI outcomes in a rat ischemia-reperfusion model.
Chu C; Delić D; Alber J; Feger M; Xiong Y; Luo T; Hasan AA; Zeng S; Gaballa MMS; Chen X; Yin L; Klein T; Elitok S; Krämer BK; Föller M; Hocher B
Biomed Pharmacother; 2022 Sep; 153():113357. PubMed ID: 35792391
[TBL] [Abstract][Full Text] [Related]
18. Delayed ischaemic contracture onset by empagliflozin associates with NHE1 inhibition and is dependent on insulin in isolated mouse hearts.
Uthman L; Nederlof R; Eerbeek O; Baartscheer A; Schumacher C; Buchholtz N; Hollmann MW; Coronel R; Weber NC; Zuurbier CJ
Cardiovasc Res; 2019 Aug; 115(10):1533-1545. PubMed ID: 30649212
[TBL] [Abstract][Full Text] [Related]
19. PPAR-alpha activation protects the type 2 diabetic myocardium against ischemia-reperfusion injury: involvement of the PI3-Kinase/Akt and NO pathway.
Bulhak AA; Jung C; Ostenson CG; Lundberg JO; Sjöquist PO; Pernow J
Am J Physiol Heart Circ Physiol; 2009 Mar; 296(3):H719-27. PubMed ID: 19151258
[TBL] [Abstract][Full Text] [Related]
20. Empagliflozin attenuates ischemia and reperfusion injury through LKB1/AMPK signaling pathway.
Lu Q; Liu J; Li X; Sun X; Zhang J; Ren D; Tong N; Li J
Mol Cell Endocrinol; 2020 Feb; 501():110642. PubMed ID: 31759100
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
